The Marijuana Industry: Everything You Need to Know
Investors should also know that most cannabis stocks don't trade on the major U.S. stock exchanges. Marijuana companies listed on major exchanges can't do business where it's illegal at the federal level, so cannabis companies are either avoiding the U.S. market or choosing to hold off on listing their shares on the New York Stock Exchange or Nasdaq.
As a result, the company you might want to buy could be listed on the less regulated over-the-counter (OTC) market, or it might be available on a foreign exchange, such as the Toronto Stock Exchange. OTC stocks aren't subject to the same strict financial requirements as stocks listed on major exchanges, though. And OTC stock prices can be volatile because of limited trading volume and narrow price transparency. You may have to get special permissions from your brokerage to buy foreign stocks, and trading them means accepting currency-exchange risks that can take a bite out of your profit.
That said, this drawback may become less of a problem for individual stock investors in the future. A handful of companies targeting the marijuana market outside the U.S. listed their shares on the NYSE or Nasdaq in 2018, and more companies could follow suit -- especially if they focus on hemp, which is no longer a schedule I substance in America.
IMAGE SOURCE: GETTY IMAGES.
Marijuana growers: Stocks to buy
Canopy Growth (NYSE: CGC) and Aurora Cannabis (NYSE: ACB) are the two biggest global marijuana companies, and fortunately, shares of both companies now trade on the New York Stock Exchange.
Canopy Growth hasn't said exactly how much marijuana it plans to produce in the future, but its annualized quarterly sales finished 2018 at a pace of more than CA$300 million. Aurora Cannabis says it's targeting production of more than 500,000 kilograms of marijuana per year; in 2018, its revenue was CA$121 million.
Most of these companies' revenue has historically come from Canada's medical marijuana market. Canopy Growth estimates its medical marijuana market share at higher than 30%, and while Aurora Cannabis is smaller, it had still served 73,579 active registered patients as of the end of December 2018.
In the future, both companies will likely generate an increasing amount of their revenue from Canada's adult-use recreational market, though. Recreational sales in the Great White North began on Oct. 17, 2018, and as that market matures, it could represent a multibillion-dollar opportunity. According to Deloitte, Canada's recreational sales could total between CA$1.8 billion and CA$4.3 billion in 2019. (By comparison, Deloitte thinks medical marijuana sales there will be between CA$770 million and CA$1.79 billion for the same period.)
Investors interested in these two growers should know that only one of them has won an investment from a major U.S. business. In 2018, beer, wine, and spirits company Constellation Brands (NYSE: STZ) acquired a 38% stake in Canopy Growth for roughly $4 billion. The investment arguably gives Canopy Growth an edge over Aurora Cannabis by providing financial flexibility Canopy could use to enter new markets, as well as marketing, distribution, and regulatory experience it can leverage to avoid mishaps. In January 2019, Canopy's management announced that they will spend up to $150 million of this windfall on an innovative "Hemp Industrial Park" in New York state, making this the first Canadian grower with plans to enter the United States following the passage of the U.S. Farm Bill.
Although Aurora Cannabis hasn't taken on a big investor yet, it's arguably been the most aggressive acquirer of cannabis companies, and there's always the chance that a suitor will emerge. In 2018, Aurora's acquisitions included major medical marijuana companies CannaMed and MedReleaf, making its product lineup one of the most attractive in the industry. As of Dec. 31, 2018, Aurora Cannabis's recreational market share was 20%, while Canopy Growth's market share could have been north of 50%, based on Aurora's figures. As a result, these are the top two growers that ought to be on every investor's radar.
IMAGE SOURCE: GETTY IMAGES.
Marijuana suppliers: Stocks to buy
There are other marijuana company suppliers, but Scotts Miracle-Gro (NYSE: SMG) and KushCo Holdings (NASDAQOTH: KSHB) are the two largest publicly traded ones investors can buy.
Scotts Miracle-Gro is best known for its plant-nutrient and weed-control products, but it has aggressively been acquiring hydroponics and lighting companies to position itself as one of the marijuana industry's biggest vendors. The company is consolidating these deals under its Hawthorne banner. Hawthorne exited 2018 with quarterly sales of $140.8 million, up 84% year over year, largely because of its $450 million acquisition of major hydroponics vendor Sunlight Supply in 2018.
Sunlight Supply added $460 million in 2017 sales to Hawthorne's $290 million, so it was a game-changing acquisition for Scotts Miracle-Gro. That said, the hydroponics business hasn't been without stumbles. It enjoyed rapid growth in places like Colorado following legalization, but demand tapered off in 2018 as oversupply in mature markets caused a drop in wholesale marijuana prices. That slowdown in demand is likely to be temporary, however. Tailwinds tied to changes in hemp regulations and the legalization of marijuana in more states could help sales growth rebound in 2019.
Unlike Scotts Miracle-Gro, KushCo Holdings is focusing on marijuana packaging and processing. The company provides specialized packaging, such as tamper-resistant bottles, that comply with strict regulations in legal marijuana markets. It's the biggest of the packaging companies, and its sales surged in 2018 thanks to the opening of California's adult-use market, growing demand in Canada, and new facilities serving new markets on the East Coast (including Massachusetts). Sales rose by 177% to $52 million in fiscal 2018, and that number is expected to exceed $110 million in fiscal 2019. In addition to packaging, KushCo's Kush Energy division also sells solvents used to produce marijuana concentrates.
IMAGE SOURCE: GETTY IMAGES.
Marijuana dispensaries: Stocks to buy
The marijuana retail market consists of e-commerce storefronts and traditional dispensaries. One of the best ways to profit from growing online sales is to invest in leading e-commerce platform Shopify (NYSE: SHOP). The dispensary market is highly fragmented, with many small players, but Curaleaf Holdings (NASDAQOTH: CURLF) and MedMen (NASDAQOTH: MMNFF) have a chance to be two of the biggest retailers in America.
Companies from every industry use Shopify's internet software solutions to manage their online and physical store footprints. The company has secured deals to be the backbone behind e-commerce for cannabis in key Canadian provinces, including Ontario, Canada's largest market. It's also won contracts with vertically integrated companies operating dispensaries in Canada. Its success in landing deals to help growers, processors, and distributors comply with regulations and enforcement provides it with a platform it can leverage in the future to serve additional markets that legalize marijuana.
This is far from a marijuana pure play, though. Shopify's sales totaled $1.07 billion in 2018, up 59% over 2017; the company didn't break out how much cannabis contributed to that figure, but we can assume it wasn't a significant driver of performance. Nevertheless, Shopify is a big, fast-growing company that's turning a profit, and future cannabis revenue only makes it a more attractive growth stock to consider buying.
As for Curaleaf, the company was operating 42 dispensaries in the U.S. as of January 2019, as well as processing marijuana from 12 cultivation sites at 10 facilities in 13 states. Curaleaf hopes to have 69 dispensaries open by the end of this year. Most of its sales (98% as of the end of 2018) come from selling medical marijuana products under its own private-label brand, but as recreational laws are passed in states with existing medical-marijuana dispensaries, its revenue mix is likely to shift.
Curaleaf is primarily an East Coast operator. In terms of store count, Florida is its biggest state, with 22 locations as of February 2019 and plans for 13 more before the end of the year. Nationwide, management plans to open about one new store per week in 2019. It also has the opportunity to grow through acquisitions; its October 2018 IPO added more than $400 million to its balance sheet.
MedMen has big aspirations, too. The company operates 20 dispensaries in five states, including nine stores in California. Those California stores accounted for 90% of revenue in 2018, but a deal to acquire medical marijuana grower PharmaCann will diversify it across more states. If the deal goes off without a hitch, it will increase MedMen's store count to 30 dispensaries, with an opportunity to open up to 78 stores across 12 states. That said, between MedMen and Curaleaf, MedMen may be riskier because it doesn't have as much cash in the bank. At the end of fiscal 2018, MedMen's cash stockpile was $79 million.
IMAGE SOURCE: GETTY IMAGES.
Marijuana pharmaceuticals: Stocks to buy
If you're interested in investing in marijuana drugmakers, you could invest in growers that are conducting clinical trials, including Canopy Growth. But if you want to invest in a company with an FDA-approved CBD drug on the market in the United States, GW Pharmaceuticals (NASDAQ: GWPH) is your only option.
GW Pharmaceuticals is a UK-based drug developer that has been studying the safety and effectiveness of marijuana's cannabinoids since the 1990s. It has marketed the THC drug Sativex, which treats muscle spasticity in multiple sclerosis, in the European Union for years, but the company only recently launched its first drug, Epidiolex, in America.
Epidiolex is a purified CBD oil that secured an FDA green light in 2018 following human trials showing it reduces seizures in patients with two treatment-resistant forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. These forms of epilepsy can be debilitating, and existing anti-epileptic medications have historically proven inadequate in controlling them. In its trials, Epidiolex reduced the number of monthly seizures patients were experiencing by 40% to 50%. Its effectiveness won it an OK from the FDA in June 2018, and it officially became available in November after the Drug Enforcement Agency classified it as a Schedule V drug. The least stringent classification in the schedule, Schedule V also includes cough syrup containing codeine.
Dravet syndrome and Lennox-Gastaut syndrome are rare, affecting roughly 70,000 people, but if Epidiolex can make its way into wider usage, its commercial opportunity could be significant. GW Pharmaceuticals has priced it at $32,500 per year and expects insurers to cover it widely. Approximately one-third of the 3.4 million people in the U.S. with epilepsy don't adequately respond to other treatment alternatives.
Image source: Getty Images.
Don't ignore the risks
Despite the size of the opportunity associated with legalizing $150 billion in global marijuana sales, marijuana investing isn't for the faint of heart. The industry is only now emerging, and many of the companies angling for market share today may wind up falling shy of sky-high predictions -- or, worse, going bankrupt. Nevertheless, the potential here is significant enough to warrant investors' attention. Just make sure you're willing to do your homework. You want to thoroughly understand the industry and the companies you're interested in owning before you buy.
More From The Motley Fool
- 10 Best Stocks to Buy Today
- 3 Stocks That Are Absurdly Cheap Right Now
- 5 Warren Buffett Principles to Remember in a Volatile Stock Market
- The $16,728 Social Security Bonus You Cannot Afford to Miss
- The Must-Read Trump Quote on Social Security
- 10 Reasons Why I'm Selling All of My Apple Stock
Todd Campbell owns shares of KushCo Holdings and Shopify. The Motley Fool owns shares of and recommends Shopify. The Motley Fool recommends Constellation Brands and KushCo Holdings. The Motley Fool has a disclosure policy.
- 1
- 2